EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Cost minimization analysis of subcutaneous and intravenous immunoglobulin treatment in Italy

Chiara Bini iD, Matteo Scortichini, Silvia Ripoli, Laura Fioravanti, Carmela Papa iD, Paolo Sciattella

Global and Regional Health Technology Assessment · 01.05.2026 · 13 (1) · 109-117

DOI: 10.33393/grhta.2026.3642 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Global and Regional Health Technology Assessment, online erschienen am 01.05.2026. Verfasst von Chiara Bini und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Economics and International Studies-Economic Evaluation and Health Technology Assessment, Faculty of Economics, University of Rome "Tor Ve…. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Human immunoglobulins are the standard of care for patients with immunodeficiencies and represent a first-line treatment for chronic inflammatory demyelinating polyneuropathy (CIDP). This study aimed to evaluate costs associated with facilitated subcutaneous (fSCIG), conventional subcutaneous (cSCIG), and intravenous (IVIG) administration of immunoglobulin in patients with primary or secondary immunodeficiency (PID and SID, respectively) and in patients with CIDP in Italy.

Methods

A cost-minimization analysis from a societal perspective was developed, considering a one-year follow-up. Direct costs included acquisition and administration costs, while indirect costs were evaluated considering productivity loss due to in-hospital IVIG using a Human Capital Approach. The posology considered for immunodeficiency disorders and CIDP was obtained from observational studies and clinical trials, respectively. Subcutaneous and intravenous administration costs were obtained from published literature. Scenario analyses were conducted to test the key assumptions of the model.

Results

This study indicates a potential reduction of annual societal expenditure in Italy of approximately €2,145 and €1,605 with fSCIG treatment in PID patients compared to cSCIG and IVIG, respectively. In SID patients, fSCIG would result in a reduction of societal expenditure of approximately €2,145 and €2,071 compared to cSCIG and IVIG. For CIDP patients, fSCIG treatment would result in a reduction of societal expenditure of €8,060 and €15,873 compared to cSCIG and IVIG, respectively.

Conclusion

The use of fSCIG for patients with PIDs, SIDs or CIDP could lead to a reduction in the direct and indirectcosts associated with the treatment of patients.

Schlagwörter

Stichwörter der Autor:innen

Chronic inflammatory demyelinating polyneuropathyCost-minimization analysisFacilitated subcutaneous immunoglobulinImmunodeficiency

Autor:innen und Institutionen

  • Centre for Economics and International Studies-Economic Evaluation and Health Technology Assessment, Faculty of Economics, University of Rome "Tor Vergata", Rome - Italy.
  • Patient Value & Access Department, Takeda Italia S.p.A., Rome - Italy.
  • Medical & Regulatory Department, Takeda Italia S.p.A., Rome - Italy.

ORCID-Profile: Chiara Bini, Carmela Papa

Zitieren

APA

Bini, C., Scortichini, M., Ripoli, S., Fioravanti, L., Papa, C., & Sciattella, P. (2026). Cost minimization analysis of subcutaneous and intravenous immunoglobulin treatment in Italy. Global and Regional Health Technology Assessment, 13(1), 109-117. https://doi.org/10.33393/grhta.2026.3642

Vancouver

Bini C, Scortichini M, Ripoli S, Fioravanti L, Papa C, Sciattella P. Cost minimization analysis of subcutaneous and intravenous immunoglobulin treatment in Italy. Global and Regional Health Technology Assessment. 2026;13(1):109-117. doi:10.33393/grhta.2026.3642

BibTeX
@article{Bini2026,
  author = {Bini, Chiara and Scortichini, Matteo and Ripoli, Silvia and Fioravanti, Laura and Papa, Carmela and Sciattella, Paolo},
  title = {Cost minimization analysis of subcutaneous and intravenous immunoglobulin treatment in Italy},
  journal = {Global and Regional Health Technology Assessment},
  year = {2026},
  volume = {13},
  number = {1},
  pages = {109--117},
  doi = {10.33393/grhta.2026.3642}
}
Kostenlos starten →